KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Change in Cash (2016 - 2025)

Historic Change in Cash for Neogenomics (NEO) over the last 17 years, with Q3 2025 value amounting to $9.4 million.

  • Neogenomics' Change in Cash rose 3600.69% to $9.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$197.9 million, marking a year-over-year decrease of 45491.36%. This contributed to the annual value of $24.5 million for FY2024, which is 6907.75% down from last year.
  • Latest data reveals that Neogenomics reported Change in Cash of $9.4 million as of Q3 2025, which was up 3600.69% from -$191.5 million recorded in Q2 2025.
  • Over the past 5 years, Neogenomics' Change in Cash peaked at $372.5 million during Q1 2021, and registered a low of -$250.2 million during Q2 2021.
  • In the last 5 years, Neogenomics' Change in Cash had a median value of -$2.9 million in 2022 and averaged -$4.6 million.
  • Per our database at Business Quant, Neogenomics' Change in Cash skyrocketed by 133044.81% in 2023 and then plummeted by 92633.9% in 2025.
  • Neogenomics' Change in Cash (Quarter) stood at -$26.9 million in 2021, then soared by 89.05% to -$2.9 million in 2022, then skyrocketed by 1330.45% to $36.2 million in 2023, then plummeted by 86.15% to $5.0 million in 2024, then surged by 87.13% to $9.4 million in 2025.
  • Its Change in Cash stands at $9.4 million for Q3 2025, versus -$191.5 million for Q2 2025 and -$20.8 million for Q1 2025.